Recombinant Mouse CTACK (CCL27)
- Known as:
- Recombinant Mouse CTACK (CCL27)
- Catalog number:
- chm-013
- Product Quantity:
- 5
- Category:
- -
- Supplier:
- Prospecbio
- Gene target:
- Recombinant Mouse CTACK (CCL27)
Related genes to: Recombinant Mouse CTACK (CCL27)
- Gene:
- CCL27 NIH gene
- Name:
- C-C motif chemokine ligand 27
- Previous symbol:
- SCYA27
- Synonyms:
- ALP, ILC, CTACK, skinkine, ESkine, PESKY, CTAK
- Chromosome:
- 9p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-07-30
- Date modifiied:
- 2016-10-05
Related products to: Recombinant Mouse CTACK (CCL27)
Related articles to: Recombinant Mouse CTACK (CCL27)
- Vesicular cutaneous lupus erythematosus (VCLE) is a rare autoimmune disease in dogs and is considered the canine counterpart of human subacute cutaneous lupus erythematosus (SCLE). However, the molecular mechanisms underlying VCLE remain incompletely defined. - Source: PubMed
Publication date: 2026/05/11
Keating TreasaStranahan LaurenWiener DominiqueKeating M KellyLeon RenatoBanovic Frane - My research has focused on optimizing drug delivery system (DDS) related gene and cell therapies. In my gene therapy research, I first developed a polyethylene glycol (PEG)-conjugated adenovirus vector (PEG-Ad) to allow modulation of adenovirus pharmacokinetics and achieve tumor targeting. Evaluating correlations between PEG-Ad blood retention, tumor tissue delivery, liver accumulation, and gene expression is an important step toward creating tumor-targeting PEG-Ad, demonstrating that a 90% PEGylation rate optimally reduced liver accumulation and improved tumor targeting via enhanced permeability and retention. To enhance tumor targeting specificity, we designed Cys-Gly-Lys-Arg-Lys (CGKRK)-PEG-Ad, in which the tumor-targeting peptide CGKRK was attached to the end of the PEG chain. Although CGKRK-PEG-Ad exhibited similarly reduced liver accumulation to that of PEG-Ad, its tumor delivery was higher than that of PEG-Ad, demonstrating its potent therapeutic efficacy against metastatic tumors. Next, I worked to optimize tumor immunotherapy by controlling immune cells in vivo dynamics. In this study, cytokines were used to activate antitumor immune cells, and chemokines were used to induce intratumoral infiltration by antitumor immune cells. While intratumoral administration of Arg-Gly-Asp (RGD)-Ad-C-C motif chemokine ligand 27 (CCL27) alone did not produce an antitumor effect against OV-HM tumors; however, co-administration with RGD-Ad-interleukin-12 (IL-12) demonstrated a stronger antitumor effect than administration of RGD-Ad-IL-12 alone. Infiltration of cluster of differentiation 3 (CD3)- and perforin-positive cells into tumor tissues was increased by combined administration of RGD-Ad-CCL27 and RGD-Ad-IL-12 compared with administration of RGD-Ad-IL-12 alone. These results demonstrate the importance of controlling the in vivo dynamics of antitumor immune cells. - Source: PubMed
Nakagawa Shinsaku - Osimertinib is a primary treatment for patients with EGFR-mutated non-small cell lung cancer. But a significant number of patients receiving Osimertinib treatment suffer from cutaneous toxicity, which includes symptoms such as rash, itching, and hair loss. This study aims to help clinical patients suffering from cutaneous toxicity to improve their quality of life. Mice treated with 50 mg/kg/day Osimertinib for 42 days exhibited different levels of cutaneous toxicity. PI/Annexin-V apoptosis assay and western blotting were used to assess keratinocyte apoptosis and DNA damage. Osimertinib upregulated inflammatory factors including CCL2, CCL27, and IL18. Glycyrrhizic acid (GA) is the most important active ingredient in licorice with pharmacological effects such as anti-inflammatory, antiviral, and anti-apoptotic. Due to its rich bioactivity, the research about GA has always been popular. However, the effects of it on relieving cutaneous toxicity have not been studied yet. We have explored the therapeutic effects and mechanisms of GA on keratinocytes and C57BL/6 mice. Thirty milligrams/kg/day of GA could effectively reduce the frequency and severity of cutaneous toxicity induced by Osimertinib, restore epidermal thickness in mice, reduce DNA damage, and lower the expression levels of inflammatory factors. Our results indicated that GA could potentially mitigate the cutaneous toxicity caused by Osimertinib, which could position it as a promising adjunct in clinical practice. - Source: PubMed
Publication date: 2026/04/01
Wang CongyingLu JiabinFu HuangxiFeng XuejingXu ZhifeiLuo PeihuaYang BoHe QiaojunYang Xiaochun - Psoriasis is a refractory immune-related disease. In recent years, it has been discovered that mesenchymal stem cells (MSCs) can be used as a new therapeutic approach for psoriasis, but their potential therapeutic mechanism remains unclear. This study aims to explore the role of MSCs in the treatment of psoriasis. - Source: PubMed
Publication date: 2026/03/28
Lin QingJi YunfeiYang BinZhu RongjiaSong PingZhao Robert Chunhua - Reliable biomarkers for the routine diagnostics of low-grade prosthetic joint infection (PJI) remain an unmet clinical need. - Source: PubMed
Publication date: 2026/03/28
Trajerova MarketaKriegova EvaShrestha BishuKudelka MilosSavara JakubGallo Jiri